Navigation Links
Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology
Date:10/25/2011

en treated with XEOMIN worldwide since 2005. The U.S. is the 20th country to approve XEOMIN for the treatment of cervical dystonia and blepharospasm.

XEOMIN is the only botulinum toxin product that does not require refrigeration prior to reconstitution. XEOMIN is available in 50-unit and 100-unit vials, which Merz believes may allow for more precise billing and reduce wastage.  

Financial Assistance and Reimbursement Support Services Merz offers two comprehensive programs to provide patients with financial assistance for XEOMIN. The XEOMIN Patient Co-payment Program is easy-to-use and offers eligible patients, who are appropriate for treatment with XEOMIN as determined by their physician, assistance for their actual out-of-pocket costs for treatment with XEOMIN. To be eligible, patients must be at least 18 years of age, currently have commercial health insurance that covers treatment costs for XEOMIN, not be enrolled in or eligible for Medicare, Medicare Advantage, Medicaid, Managed Medicaid, TRICARE (i.e., CHAMPUS), or other state or federally funded insurance plan, and not be a resident in the state of Massachusetts. Eligible treatment-related costs may include the cost of XEOMIN, associated guidance therapy and related administration fees.

The XEOMIN Patient Assistance Program provides XEOMIN at no cost to eligible patients who are experiencing financial hardship, do not have third-party drug coverage, and who are not eligible for government-funded drug programs.

For more information about reimbursement support and financial assistance programs for XEOMIN, visit www.XEOMIN.com, or call 1-888-4-XEOMIN (1-888-493-6646). Dedicated support representatives are available from 8 a.m. until 8 p.m. (EDT), Monday through Friday.

IMPORTANT SAFETY INFORMATIONWARNING: DISTANT SPREAD OF TOXIN EFFECTPostmarketing reports indicate that the effects of XEOMIN and all botulinum toxin products
'/>"/>

SOURCE Merz Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. FDA Approves Merz Pharmaceuticals Xeomin® (incobotulinumtoxinA) for the Treatment of Cervical Dystonia and Blepharospasm
2. Xeomin® (incobotulinumtoxinA) - a Botulinum Toxin Free From Accessory Proteins - Now Available in the U.S.
3. Xeomin® (incobotulinumtoxinA) Data To Be Presented At The 71st Annual Assembly Of The American Academy Of Physical Medicine And Rehabilitation
4. Merz Pharmaceuticals Introduces Comprehensive Programs to Provide Patients With Financial Assistance for Xeomin® (incobotulinumtoxinA)
5. Merz Pharmaceuticals Announces New Centers for Medicare and Medicaid Billing Q-Code for Xeomin® (incobotulinumtoxinA)
6. New Data On Xeomin® (IncobotulinumtoxinA) To Be Presented At The 15th International Congress Of Parkinsons Disease And Movement Disorders (MDS)
7. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
10. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
11. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 2014  Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ... healthcare conferences during the third quarter, the 2014 Avondale ... Healthcare 2014 Conference.  Alexza,s corporate presentation will be webcast ... each event are below: , 2014 Avondale ... Boston , MA.  The format is ...
(Date:7/29/2014)... ROCKVILLE, Md. , July 29, 2014  Synthetic ... anti-infective biologic and drug candidates targeting specific pathogens that ... view of the unusual market activity in the Company,s ... Company in accordance with its usual practice. The Company ... unusual market activity. About Synthetic Biologics, Inc. ...
(Date:7/29/2014)... 2014 Numotion,s Board of Directors has announced that ... be the company,s new Chief Executive Officer. ... GE where he worked primarily for GE Healthcare Services, running ... $5 billion. His most recent position was as President and ... am thrilled to join Numotion," said Mike Swinford . ...
Breaking Medicine Technology:Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 2Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 3Synthetic Biologics, Inc. States that Its Policy is Not to Comment on Unusual Market Activity 2Numotion Names Mike Swinford CEO 2
... , , ... Group (MRG), the global authority on medical technology market intelligence, ... enteral feeding devices will be a key driver of the ... MRG,s new US and European Markets for Enteral Feeding ...
... , FORT COLLINS, Colo., Dec. 14 ... 250 mg (chenodiol tablets). On October 22, 2009, ... an important therapy for patients suffering from gallstones in ... disease or advanced age. , Chenodal prescriptions have started ...
Cached Medicine Technology:Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 2Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 3Manchester Announces Availability of Chenodal(TM) 2
(Date:7/29/2014)... 2014)A diet rich in soy may help feminine hearts, ... today in Menopause , the journal of The ... to the diet of women in Asia, produces the ... similar to Asian migrants to North America, leads to ... and switching to soy from a Western diet after ...
(Date:7/29/2014)... July 29, 2014 Daily Gossip indicates in ... method was created for any sufferer who is looking for ... The author of the new program, Sarah Summer, says that ... suffered from yeast infection, too. Actually, this is the reason ... this problem. , The Natural Cure for Yeast ...
(Date:7/29/2014)... Port Washington, New York (PRWEB) July 29, 2014 ... dedicated to protecting the rights of victims injured by ... action lawsuit has been filed by plaintiffs in Canada ... increased risk of cardiovascular events with the low ... was filed on July 22, 2014 in the Ontario ...
(Date:7/29/2014)... Regardless of the good things that ... to share those with. Love is about understanding, commitment ... Love is also about overcoming all the challenges that ... perfect relationship, women need to know how to understand ... Him program, please visit the official website at ...
(Date:7/29/2014)... of severe combat injuries threatening more than one limb, ... record of safety and effectiveness in avoiding amputation, reports ... Plastic and Reconstructive Surgery , the official medical ... (ASPS). , Experience with multiple limb salvage procedures ... success rates, with no increase in complications compared to ...
Breaking Medicine News(10 mins):Health News:Soy may help women's hearts if they start early 2Health News:Natural Cure for Yeast Infection Review Reveals Sarah Summer’s Healing Method 2Health News:Class Action Lawsuit in Canada Alleges Manufacturer of Delatestryl Testosterone Injection Failed to Warn of Cardiovascular Risks, Parker Waichman LLP Reports 2Health News:Class Action Lawsuit in Canada Alleges Manufacturer of Delatestryl Testosterone Injection Failed to Warn of Cardiovascular Risks, Parker Waichman LLP Reports 3Health News:How to Reach the Heart of the Perfect Guy with "Enchant Him Program" - a Report by Daily Gossip Magazine 2Health News:Good outcomes with multiple limb salvage after severe combat injuries, reports Plastic and Reconstructive Surgery 2
... TALLAHASSEE, Fla., Aug. 12 With the recent increase in ... in these already hard economic times - do they pay the ... those who want to quit, The Florida Quitline (1-877-U-CAN-NOW) is here ... , , According to Kim Berfield, Deputy Secretary ...
... , , , , ... a leading provider of Linux-bas e d ... Systems, a national health care management company, has deployed Arkeia Network Backup. ... Goold has realized dramatic improvements in backup performance and in backup administration. ...
... Fountain Healthy Aging,Inc. announced on August 12 2009 that ... Oak Resources Limited which provides the Company,with a $5,000,000 Equity ... has the right to draw down from the Equity Line,Investment ... of 24 months. The,first tranche investment of $1,000,000 was drawn ...
... , WESTFIELD, Ind., Aug. 12 maxIT ... healthcare providers, announced the successful "Stage 6" designation of Gila ... in Silver City, New Mexico. maxIT assisted the Phoenix Health ... to support the implementation of several HIS modules. Beginning ...
... , , , ... (NYSE: HI ) -- Hillenbrand, Inc. reported net revenues of ... 2009, a $6.3 million (3.8 percent) decline from the same period in ... million (4.9 percent) decline. The difference in as-adjusted net income for the ...
... , , , ... create expensive home health care costs. Poorly designed mobility aids or ... issue only part of the need is addressed which creates mobility ... alleviated if mobility issues were detected and properly addressed. , ...
Cached Medicine News:Health News:The Time To Quit Is Now -- Free NRT Is Available 2Health News:Goold Health Systems Accelerates Backups by 5-times Using Arkeia Network Backup 2Health News:Goold Health Systems Accelerates Backups by 5-times Using Arkeia Network Backup 3Health News:Fountain Healthy Aging Inc Announces $5,000,000 Equity Line Of Credit Investment Secured 2Health News:Fountain Healthy Aging Inc Announces $5,000,000 Equity Line Of Credit Investment Secured 3Health News:maxIT Assists Medical Center to Achieve Prestigious Stage 6 Recognition 2Health News:maxIT Assists Medical Center to Achieve Prestigious Stage 6 Recognition 3Health News:Hillenbrand Reports 2.4% Decline in Earnings Per Share on 3.8% Lower Revenues in Third Quarter 2009 2Health News:Hillenbrand Reports 2.4% Decline in Earnings Per Share on 3.8% Lower Revenues in Third Quarter 2009 3Health News:Hillenbrand Reports 2.4% Decline in Earnings Per Share on 3.8% Lower Revenues in Third Quarter 2009 4Health News:Hillenbrand Reports 2.4% Decline in Earnings Per Share on 3.8% Lower Revenues in Third Quarter 2009 5Health News:Hillenbrand Reports 2.4% Decline in Earnings Per Share on 3.8% Lower Revenues in Third Quarter 2009 6Health News:Hillenbrand Reports 2.4% Decline in Earnings Per Share on 3.8% Lower Revenues in Third Quarter 2009 7Health News:Hillenbrand Reports 2.4% Decline in Earnings Per Share on 3.8% Lower Revenues in Third Quarter 2009 8Health News:Hillenbrand Reports 2.4% Decline in Earnings Per Share on 3.8% Lower Revenues in Third Quarter 2009 9Health News:Hillenbrand Reports 2.4% Decline in Earnings Per Share on 3.8% Lower Revenues in Third Quarter 2009 10Health News:Hillenbrand Reports 2.4% Decline in Earnings Per Share on 3.8% Lower Revenues in Third Quarter 2009 11Health News:Hillenbrand Reports 2.4% Decline in Earnings Per Share on 3.8% Lower Revenues in Third Quarter 2009 12Health News:Expensive Health Care: Undetected, Unmet Mobility Needs Creating Boomer & Senior Health Care Costs 2
... there is a more efficient way ... fully portable battery operated patient warming ... surgical teams with a compact and ... the entire surgical process. Its unique ...
... patient warming system consists of our ... range of blankets for use with ... clinical applications. Blankets are available for ... and paediatric sizes and a sterile ...
MAMMOMAT 3000 Nova supports high-volume screening as well as interventional diagnostics. Versatile procedural capabilities include magnification, stereotactic biopsy, needle localization, and specime...
The Synoptiscope(L-2510B) has a wide variety of functions including binocular function diagnosis and treatment....
Medicine Products: